Parkinson Disease
Conditions
Brief summary
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease. 3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.
Detailed description
1. Objective to evaluate the tolerance and safety of multiple administration of fenloramide tablets in patients with early and mid-term Parkinson's disease: To evaluate the adverse events of DLT and MTD, adverse reactions, clinical laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, stool routine), vital signs, 12 lead ECG and physical examination of fenloramide tablets in patients with early and mid-term Parkinson's disease . 2. Objective to evaluate the pharmacokinetics of fenloramide tablets in patients with Parkinson's disease in early and middle stages. The main PK parameters included Tmax, SS, Cmax, SS, cavg, SS, Ke, T1 / 2, Cl / F (only fenloramide prototype), VZ / F (only fenloramide prototype), auc0-24, SS, aucinf, SS, auc0 last, SS, AUC\_ %Extrap, DF, etc. 3. Objective to explore the efficacy of fenloramide tablets in the treatment of early and mid-term Parkinson's disease, and to observe the changes of UPDRS and CGI.
Interventions
DRUGPhenlarmide
Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
DRUGPlacebo
Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Sponsors
Xuanwu Hospital, Beijing
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understand and sign the informed consent, understand the research process and requirements, and volunteer to participate in the study; 2. over 30 years old and have no gender limit; 3. Patients diagnosed with Parkinson's disease according to the Chinese diagnostic criteria for Parkinson's disease (2016 Edition); 4. Hoehn-Yahr grade ≤ 3; 5. The Unified Parkinson's disease scale (UPDRS) motor score (Part III) ≥ 10; 6. Not using anti Parkinson's disease drugs within 28 days before enrollment; 7. If the subjects are receiving dopamine receptor agonists (such as Pramipexole, etc.), anticholinergic drugs (such as Benzhexol Hydrochloride, etc.), monoamine oxidase B (MAO-B) inhibitors (such as Selegiline, Rasagiline, etc.), and N-methyl-D-aspartate (NMDA) receptor antagonists (such as Amantadine), they should stop using the drugs 28 days before the screening period; 8. Patients who had been treated with levodopa preparation (including levodopa compound preparation) for less than 6 months before screening, and had not received levodopa preparation treatment within 28 days before screening period.
Exclusion criteria
1. Atypical Parkinson's symptoms due to the use of drugs (such as Flunarizine, Metoclopramide), nervous system diseases, genetic metabolic diseases, encephalitis, cerebrovascular diseases or other degenerative diseases (such as progressive supranuclear paralysis); 2. Patients with dementia, active mental illness or hallucination, severe depression (Beck Depression Scale - Ⅱ ≥ 29 points at screening), or Mini-Mental State Examination (MMSE) \< 25 points; 3. Those who have received neurosurgical operation or electrical stimulation (such as pallidotomy, thalamotomy, deep brain electrical stimulation, etc.); 4. Patients with clinically significant abnormal liver function were defined as total bilirubin \> 1.5 times of the upper limit of normal value or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 times of the upper limit of normal value; 5. Patients with clinically significant renal dysfunction: creatinine clearance rate (CCR) \< 30 ml / min (using Cockcroft-Gault formula); 6. Patients with uncontrollable or severe cardiovascular diseases, including NYHA grade II or above congestive heart failure, unstable angina pectoris, myocardial infarction, arrhythmia requiring treatment at the time of screening, and QTc interval prolongation more than 480ms, in 6 months before the first administration of trial drug; 7. There is a history of heart, liver, kidney, respiratory, digestive, endocrine, immune or blood system diseases considered by researchers to be serious; 8. During the screening period, the patients with HIV positive, HBV or HCV infection and syphilis infection were active; 9. Patients with malignant tumor within 5 years before screening were excluded from cervical carcinoma in situ, skin basal cell or squamous cell carcinoma, local prostate cancer after radical operation and breast intraductal carcinoma in situ after radical operation; 10. There were significant food or drug allergy history or hypersensitivity reaction judged by researchers as having clinical significance; 11. Participants in any clinical trials within 3 months before administration of the study; 12. Pregnant or lactating women, or those whose serum hCG test is positive before trial administration, who are unable or unwilling to take contraceptive measures approved by the researcher during the study period and within 3 months after the end of the study according to the instructions of the researcher; 13. Those considered unsuitable by the researchers to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tmax, ss | through study completion, an average of 6 months | After administration, the time when the highest concentration of drug appeared in plasma |
| Efficacy evaluation | through study completion, an average of 6 months | explore the efficacy of fenolamide tablets in the treatment of early and middle stage Parkinson's disease, and observe the changes of UPDRS and CGI. |
| maximum tolerable dose (MTD) | through study completion, an average of 6 months | The occurrence of Maximum tolerable dose. |
| adverse events | through study completion, an average of 6 months | The occurrence rate of adverse events. |
| adverse reactions | through study completion, an average of 6 months | The occurrence rate of adverse reactions |
| blood routine | through study completion, an average of 6 months | Check whether the red blood cell system, white blood cell system and platelet system are normal |
| the dose limiting toxicity (DLT) | through study completion, an average of 6 months | The occurrence of Dose limiting toxicity. |
| blood biochemistry | through study completion, an average of 6 months | The contents of various ions, sugars, lipids, proteins, enzymes, hormones and metabolites in blood were detected |
| coagulation function | through study completion, an average of 6 months | Four coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB) were evaluated. |
| urine routine | through study completion, an average of 6 months | Urine routine examination includes urine color, transparency, pH, red blood cells, white blood cells, epithelial cells, tube type, protein, specific gravity and urine sugar. |
| stool routine | through study completion, an average of 6 months | Routine stool tests include the detection of red and white blood cells in feces, bacterial sensitivity test, occult blood test (OB) and inspection of eggs. |
| Body temperature | through study completion, an average of 6 months | One of the vital signs. |
| 12 lead ECG | through study completion, an average of 6 months | Evaluation of QT interval |
| Blood pressure | through study completion, an average of 6 months | Assess whether systolic blood pressure and diastolic blood pressure are normal. |
| Heart rate | through study completion, an average of 6 months | One of the vital signs. |
| Breathing | through study completion, an average of 6 months | Assess if breathing is normal |
| Cmax, ss | through study completion, an average of 6 months | The highest concentration of the drug in the plasma after administration |
| Cavg, ss | through study completion, an average of 6 months | The quotient of the area under the plasma concentration time curve divided by the interval time within a dose interval after the plasma concentration reaches the steady state. |
| Ke | through study completion, an average of 6 months | The ratio of the amount of compound eliminated from the body to the total amount in the body in unit time |
| t1/2 | through study completion, an average of 6 months | The time required for the concentration of a drug to drop by half in an organism |
| CL/F (fenoxamide prototype only) | through study completion, an average of 6 months | The amount of a substance excreted by the kidney per minute |
| Vz/F (fenoxamide prototype only) | through study completion, an average of 6 months | After the drug reaches dynamic equilibrium in the body, the ratio of the drug dose in the body to the blood concentration is called the apparent distribution volume |
| AUC0-24, ss | through study completion, an average of 6 months | After administration, the area under the 0-24 hour time curve of blood concentration absorbed into human circulation |
| AUCinf, ss | through study completion, an average of 6 months | After administration, the area under the time curve of 0-infinity of the blood concentration absorbed into human circulation |
| AUC0-last，ss | through study completion, an average of 6 months | After administration, the area under the time curve of 0-the last accurately determined sample collection time of the blood concentration absorbed into human circulation |
| AUC_%Extrap | through study completion, an average of 6 months | the area under the curve that has been derived after extrapolation of Residual Area |
| DF | through study completion, an average of 6 months | The index reflecting the unbalanced situation of transportation in time |
Countries
China
Outcome results
None listed